An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®
- Varga, Zsuzsanna
- Lebeau, Annette
- Bu, Hong
- Hartmann, Arndt
- Penault-Llorca, Frédérique
- Guerini-Rocco, Elena
- Schraml, Peter
- Symmans, Fraser
- Stoehr, Robert
- Teng, Xiaodong
- Turzynski, Andreas
- von Wasielewski, Reinhard
- Gürtler, Claudia
- Laible, Mark
- Schlombs, Kornelia
- Joensuu, Heikki
- Keller, Thomas
- Sinn, Peter
- Sahin, Ugur
- Bartlett, John
- Viale, Giuseppe
Publication date
December 2017
DOI Publisher
Springer Science and Business Media LLCAbstract
International audienceAccurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for therapeutic decision making in early breast cancer. In this multicenter prospective study, we addressed the issue of inter- and intrasite reproducibility using the recently developed reverse transcription-quantitative real-time polymerase chain reaction-based MammaTyper® test
Add to ORKG